Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The endotoxin-lipoprotein hypothesis.

M Rauchhaus1, A J Coats, S D Anker

  • 1Department of Clinical Cardiology, National Heart and Lung Institute, London, UK. m.rauchhaus@ic.ac.uk

Lancet (London, England)
|October 19, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The association between iron deficiency and outcomes: a secondary analysis of the intravenous iron therapy to treat iron deficiency anaemia in patients undergoing major abdominal surgery (PREVENTT) trial.

Anaesthesia·2022
Same author

International Exercise Recommendations in Older Adults (ICFSR): Expert Consensus Guidelines.

The journal of nutrition, health & aging·2021
Same author

Tumour biomarkers: association with heart failure outcomes.

Journal of internal medicine·2020
Same author

Novel endotypes in heart failure: effects on guideline-directed medical therapy.

European heart journal·2018
Same author

International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.

The journal of nutrition, health & aging·2018
Same author

[Iron deficiency : Recognition and treatment].

Der Internist·2017
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Statins lower cholesterol but may harm patients with chronic heart failure (CHF). Higher cholesterol might be beneficial in CHF by binding harmful lipopolysaccharides, suggesting non-lipid-lowering statins could be advantageous.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) revolutionized hypercholesterolemia treatment, reducing cardiovascular disease morbidity and mortality.
  • Simvastatin reduces new-onset heart failure events, but benefits may extend beyond lipid-lowering.
  • Low serum cholesterol is linked to impaired survival in chronic heart failure (CHF) patients, possibly due to inflammation and increased lipopolysaccharide.

Purpose of the Study:

  • To investigate the potential benefits of higher total cholesterol concentrations in CHF patients.
  • To explore the hypothesis that lipoproteins bind lipopolysaccharides, mitigating detrimental effects.
  • To propose that non-lipid-lowering statin properties (immune modulatory, anti-inflammatory) might be beneficial in CHF.

Main Methods:

Related Experiment Videos

  • Review of existing evidence on statin effects in cardiovascular disease and CHF.
  • Postulation of a mechanism involving lipoprotein binding of lipopolysaccharides.
  • Hypothesizing an optimal lipoprotein concentration for CHF patients.

    • Main Results:

    • Evidence suggests lower cholesterol may be detrimental in CHF.
    • Lipoproteins may bind lipopolysaccharides, offering a protective effect.
    • A potential threshold exists below which lipid reduction could be harmful.

    Conclusions:

    • Higher total cholesterol concentrations may be beneficial in CHF patients.
    • Lipoprotein's role in binding lipopolysaccharides warrants further investigation.
    • Non-lipid-lowering statins with immune-modulating properties could offer therapeutic advantages in CHF.